Forum's Lead Drug Program Fails In Phase III Schizophrenia Trials

Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .

Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .

While Forum – which is developing the product in partnership with Mitsubishi Tanabe Pharma –plans to analyze the data from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Eisai Pulls Another Leqembi Growth Lever With First Subcutaneous Approval

 
• By 

The US FDA approved a subcutaneous version of the Biogen-partnered anti-amyloid antibody, Leqembi IQLIK, for once-weekly maintenance dosing after 18 months of I.V. treatment every two weeks.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.

Amylyx’s Late-Stage Drug Fails In PSP, But Focus Remains On Avexitide

 

The drug that was once commercialized as Relyvrio for ALS failed to show a benefit in adults with progressive supranuclear palsy.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By 

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

More from Therapy Areas

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By 

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.